Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Multiple sclerosis

Monitoring long-term treatments in multiple sclerosis

Patients with relapsing–remitting multiple sclerosis have been shown to benefit from disease-modifying treatments over prolonged periods. More focus should now be placed on monitoring the long-term evolution of this disease (making use of tools such as MRI), alongside the patients' response and adherence to such treatments.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Doggrell, S. A. Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group. Expert Opin. Pharmacother. 11, 1225–1230 (2010).

    CAS  Article  Google Scholar 

  2. Katrych, O., Simone, T. M., Azad, S. & Mousa, S. A. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes. CNS Neurol. Disord. Drug Targets 8, 512–519 (2009).

    CAS  Article  Google Scholar 

  3. Ford, C. et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult. Scler. 16, 342–350 (2010).

    CAS  Article  Google Scholar 

  4. Brown, M. G. et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 69, 1498–1507 (2007).

    CAS  Article  Google Scholar 

  5. Trojano, M. et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann. Neurol. 61, 300–306 (2007).

    CAS  Article  Google Scholar 

  6. Cutter, G. R. et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122, 871–882 (1999).

    Article  Google Scholar 

  7. Barkhof, F., Calabresi, P. A., Miller, D. H. & Reingold, S. C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat. Rev. Neurol. 5, 256–266 (2009).

    Article  Google Scholar 

  8. Fisniku, L. K. et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann. Neurol. 64, 247–254 (2008).

    Article  Google Scholar 

  9. Sormani, M. P. et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann. Neurol. 65, 268–275 (2009).

    Article  Google Scholar 

  10. Rovaris, M. et al. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology 72, 1693–1701 (2009).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Massimo Filippi.

Ethics declarations

Competing interests

M. Filippi has acted as a consultant and received honoraria and research support from Bayer Schering Pharma, Biogen-Dompé, Genmab A/S, Merck Serono and Teva Pharmaceutical Industries.

M. A. Rocca has acted as a consultant for Bayer Schering Pharma and received honoraria from Biogen-Dompé.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Filippi, M., Rocca, M. Monitoring long-term treatments in multiple sclerosis. Nat Rev Neurol 6, 421–422 (2010).

Download citation

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing